Share on LinkedInShare on LinkedIn

ARTICLE · 05 AUGUST 2014

A Compound Is Obvious Where Only Minor Changes To A Prior Art "Lead Compound" Are Required To Make The Claimed Compound

Bristol-Myers (BMS) sued Teva for infringing a patent directed to entecavir, a nucleoside analogue with antiviral properties.

United StatesIntellectual Property

Bristol-Myers Squibb Co. v. Teva Pharms USA, Inc.

Addressing the obviousness of a claimed compound where a person of skill would need to make only minor changes to a lead compound to arrive at the claimed invention, the U.S. Court of Appeals for the Federal Circuit affirmed a district court's ruling, finding that the pharmaceutical was obvious where a skilled artisan would have altered the lead compound of the prior art in the exact same manner suggested by defendant.  Bristol-Myers Squibb Co. v. Teva Pharms USA, Inc., Case No. 13-1306 (Fed. Cir., June 12, 2014) (Chen, J.).

Bristol-Myers (BMS) sued Teva for infringing a patent directed to entecavir, a nucleoside analogue with antiviral properties. BMS markets entecavir for treating hepatitis B under the brand name Baraclude. Teva filed an Abbreviated New Drug Application (ANDA) seeking to market a generic version of entecavir accompanied by a Paragraph IV certification.  In response, BMS sued for

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from